tradingkey.logo
tradingkey.logo
Search

Ultragenyx Initiates Submission Of BLA To The U.S. FDA For DTX401 AAV Gene Therapy

ReutersAug 18, 2025 2:25 PM
facebooktwitterlinkedin

- Ultragenyx Pharmaceutical Inc RARE.O:

  • ULTRAGENYX INITIATES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION (BLA) TO U.S. FDA FOR DTX401 AAV GENE THERAPY FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA)

  • ULTRAGENYX PHARMACEUTICAL INC - PLANS TO COMPLETE FULL BLA SUBMISSION IN Q4 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI